Ieq Capital LLC Invests $561,000 in Enanta Pharmaceuticals, Inc. $ENTA

Ieq Capital LLC purchased a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 38,508 shares of the biotechnology company’s stock, valued at approximately $561,000. Ieq Capital LLC owned about 0.13% of Enanta Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Meeder Asset Management Inc. bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth $32,000. Seven Fleet Capital Management LP acquired a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at $36,000. Strs Ohio bought a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $50,000. Clearstead Trust LLC bought a new position in shares of Enanta Pharmaceuticals in the second quarter valued at about $74,000. Finally, Quarry LP acquired a new position in Enanta Pharmaceuticals during the 3rd quarter worth about $81,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ENTA has been the subject of several research reports. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $19.50.

Enanta Pharmaceuticals Stock Down 1.4%

Enanta Pharmaceuticals stock opened at $13.60 on Friday. The business’s 50-day simple moving average is $13.59 and its 200 day simple moving average is $13.48. The stock has a market cap of $396.10 million, a price-to-earnings ratio of -5.64 and a beta of 0.98. Enanta Pharmaceuticals, Inc. has a 12-month low of $7.05 and a 12-month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The firm had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. As a group, sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -2.36 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.